MedPath

湖南湘易康制药有限公司

Ownership
-
Established
2009-01-05
Employees
-
Market Cap
-
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

17

NMPA:17

Drug Approvals

Trepibutone

Product Name
曲匹布通
Approval Number
国药准字H14022898
Approval Date
Nov 16, 2023
NMPA

Adenosine Cyclophosphate

Product Name
环磷腺苷
Approval Number
国药准字H20067123
Approval Date
Sep 1, 2023
NMPA

Nitrofurazonum

Product Name
呋喃西林
Approval Number
国药准字H42020920
Approval Date
Sep 1, 2023
NMPA

Furazolidone

Product Name
呋喃唑酮
Approval Number
国药准字H42020921
Approval Date
Sep 1, 2023
NMPA

Bendazolum

Product Name
地巴唑
Approval Number
国药准字H20174104
Approval Date
Sep 2, 2022
NMPA

Resorcinol

Product Name
间苯二酚
Approval Number
国药准字H20073856
Approval Date
Sep 1, 2022
NMPA

Meglumine

Product Name
葡甲胺
Approval Number
国药准字H43020819
Approval Date
Mar 2, 2021
NMPA

Bismuth Subnitrate

Product Name
次硝酸铋
Approval Number
国药准字H43021489
Approval Date
Feb 21, 2020
NMPA

Methyldopa Tablets

Product Name
甲基多巴
Approval Number
国药准字H43020748
Approval Date
Feb 21, 2020
NMPA

Diatrizoic Acid

Product Name
泛影酸
Approval Number
国药准字H43021512
Approval Date
Feb 21, 2020
NMPA
  • Prev
  • 1
  • 2
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.